ArsenalBio Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 127

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $325M

  • Investors
  • 25

ArsenalBio General Information

Description

Operator of a programmable cell therapy company intended to discover, develop, and commercialize curative immune cell therapies. The company offers a full-stack research and development engine that generates multifunctional T-cell medicines, enabled by the specific insertion of large synthetic deoxyribonucleic acid sequences, enabling clinicians with next-generation autologous T-cell therapies to defeat cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 329 Oyster Point Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 329 Oyster Point Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ArsenalBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 04-Sep-2024 $325M Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 18-Nov-2022 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 17-Oct-2019 $85M $85M Completed Clinical Trials - Phase 1
To view ArsenalBio’s complete valuation and funding history, request access »

ArsenalBio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 18,967,560 $0.000010 $0.36 $4.53 $4.53 1x $4.53 19.05%
To view ArsenalBio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ArsenalBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a programmable cell therapy company intended to discover, develop, and commercialize curative immune cell th
Drug Discovery
South San Francisco, CA
127 As of 2026

Emeryville, CA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ArsenalBio Competitors (85)

One of ArsenalBio’s 85 competitors is Eureka Therapeutics, a Venture Capital-Backed company based in Emeryville, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eureka Therapeutics Venture Capital-Backed Emeryville, CA
Nkarta Therapeutics Formerly VC-backed South San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Arvinas Formerly VC-backed New Haven, CT
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
You’re viewing 5 of 85 competitors. Get the full list »

ArsenalBio Patents

ArsenalBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260355246-A1 Systems targeting psca and psma and methods of use thereof Pending 02-May-2025
WO-2026232118-A1 Systems targeting psca and psma and methods of use thereof Pending 02-May-2025
WO-2026151965-A1 Shrna targeting fas and tgfbrii genes Pending 10-Jan-2025
WO-2026055342-A1 Synthetic pathway activators Pending 04-Sep-2024
AU-2025238278-A1 Antigen binding proteins that bind tmprss4 and methods of use thereof Pending 20-Mar-2024 C07K16/40
To view ArsenalBio’s complete patent history, request access »

ArsenalBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ArsenalBio Investors (25)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
Luma Group Accelerator/Incubator Minority
Milky Way Investments Group Venture Capital Minority
NVentures Corporate Venture Capital Minority
Regeneron Ventures Corporate Venture Capital Minority
You’re viewing 5 of 25 investors. Get the full list »

ArsenalBio FAQs

  • When was ArsenalBio founded?

    ArsenalBio was founded in 2018.

  • Where is ArsenalBio headquartered?

    ArsenalBio is headquartered in South San Francisco, CA.

  • What is the size of ArsenalBio?

    ArsenalBio has 127 total employees.

  • What industry is ArsenalBio in?

    ArsenalBio’s primary industry is Drug Discovery.

  • Is ArsenalBio a private or public company?

    ArsenalBio is a Private company.

  • What is the current valuation of ArsenalBio?

    The current valuation of ArsenalBio is .

  • What is ArsenalBio’s current revenue?

    The current revenue for ArsenalBio is .

  • How much funding has ArsenalBio raised over time?

    ArsenalBio has raised $631M.

  • Who are ArsenalBio’s investors?

    ARCH Venture Partners, Luma Group, Milky Way Investments Group, NVentures, and Regeneron Ventures are 5 of 25 investors who have invested in ArsenalBio.

  • Who are ArsenalBio’s competitors?

    Eureka Therapeutics, Nkarta Therapeutics, Adaptimmune Therapeutics, Arvinas, and Carisma Therapeutics are some of the 85 competitors of ArsenalBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process